(This Oct. 5 factbox has been corrected to fix the entry on GLP-1 analogues to say the trial will likely be completed in mid-2023, not during the fourth quarter) FRANKFURT (Reuters) – New breakthrough drugs that tackle obesity and kidney damage could make a dent in the $50 billion U.S. dialysis market. The following are facts about the new treatment options and what role they play in slowing the gradual progression of chronic kidney disease that can end in renal failure. Two classes of drugs, originally designed as diabetes treatments, have been found to have additional benefits to treat condi…